Latest Conference Articles

Heart failure is diabetes’ most sinister, most overlooked complication

AACE speakers on the challenge of managing patients’ adrenal conditions

Peter Goadsby, M.B., B.S., Director of the NIHR- Wellcome Trust King’s Clinical Research, London, Professor of Neurology, University of California at San Francisco, explained the benefits of the recent FDA approval of the gammaCore non-invasive vagal nerve stimulator on patients suffering from cluster headaches.

At AACE 2017, Shashank Joshi, MD, Lilavati Hospital and Research Centre, Mumbai explained his team’s simple diabetes treatment formula: A for A1C, B for blood pressure, C for cholesterol (LDL cholesterol), and D for diet that’s culturally sensitive and adaptable.

Shashank Joshi, MD, Lilavati Hospital and Research Centre, Mumbai, spoke to MD Magazine about the cultural considerations when attempting to personalize diabetes care.

Somatropin increased HDL-C levels in patients with GHD at 24 months.

A new category of cardiovascular “extreme risk” has LDL-C goals of

In terms of specific endocrine functions, bones favor glucose metabolism and homeostasis and are necessary for memory formation and for muscle function during exercise. Gerard Karsenty, MD, PhD also explained that osteo-calcium is not only necessary to foster this function, but it’s also sufficient, and can improve this function in animals.

More research and education could to prevent inherent risks

Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine addressed that there were several medications in the pipeline being tested for different aspects of epilepsy treatment.

AT AAN 2017, Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine spoke with MD Magazine about the latest advancements in epilepsy research.

Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics also discussed their team’s programs in type 2 diabetes. One is an activator of an enzyme called glucocynase – a master regulator for glucose in the body. According to Altstiel, when glucose is too high, it either shuns it off to energy production or stores it in the form of glycogen. It’s an insulin independent way of how the body controls glucose.

“This phase 2b study did exactly what we wanted a phase 2 study to do, which was to establish a patient population in mild patients and also find a safe and well tolerated dose,†said Larry Altstiel, MD, PhD.

Follow-up data from TOPIC, CARE-MS II trials positive for the two MS drugs.

“This appears to be a very safe and effective drug, and is a valuable part of our therapeutic armamentarium. I don’t think teriflunomide addresses all the unmet needs in MS, in fact, no drug meets all the unmet needs, but this is a very well tolerated oral agent.”

The nearly 7-year extension trial presented a 47% reduction overall in conversion to clinically definite MS with those patients who had been on 14mg of teriflunomide from the beginning.

Ocrevus reduced all 3 aspects of relapsing MS disease: reduction relapses, reduction disability, and reduction lesions within the brain quite substantially.

Tecfidera and Tysabri can provide MS patients with positive outcomes.

“Unlikely to have clinically relevant interactions with any commonly prescribed AEDs.”

Patients with tardive dyskinesia were previously only looked at, not treated.

The treatment of tardive dyskinesia can improve the impact of the condition on these very complicated patients.

“When we make recommendations, we don’t just use the evidence from the studies.”

Study results coincide with FDA's recent decision on a stimulation device.

Kids with lower limb spasticity should be given Dysport.

Those treated experienced an average decrease of 2.9 monthly migraine days.

Researchers previously only considered ALS as one illness, but new knowledge has changed that mentality and has shown experts they need to personalize treatment approaches. “It’s important to understand the disease in different groups of people.”

Risk of death in epilepsy "almost the elephant in the room,” according to Donner.

"This is disease-specific, mechanism-based treatment," Amaal Starling enthuses.

Past studies of AF have under-represented women, according to Louise McCullough.